背景:网络药理学领域显示出重大发展。网络药理学的概念与中医哲学有许多相似之处,使其适合了解中医治疗复杂疾病的作用机理,例如缺血性心脏病(IHD)。
目的:本文综述了网络药理学在破译中药治疗IHDs机制方面的代表性应用。
方法:在本报告中,我们使用\"缺血性心脏病\"或\"冠心病\"或\"冠状动脉疾病\"或\"心肌缺血\"AND(\"网络药理学\"或\"系统药理学\")作为关键词搜索PubMed的出版物,WebofScience,和GoogleScholar数据库,然后分析了具有代表性的研究报告,总结和验证了中药活性成分和靶标网络在改善IHD中的作用,以显示网络药理学在中药研究中应用的优势和不足。
结果:网络药理学研究表明,HGF,PGF,MMP3,INSR,PI3K,MAPK1,SRC,VEGF,VEGFR-1,NO,eNOS,NO3,IL-6,TNF-α,更多是中医的主要目标。芹菜素,25S-大茎皂甙P,人参皂苷Re,Rb3,Rg3,射翔新同宁,秋水仙碱,干姜-乌头汤,速效心通滴丸,人参-丹参药物对和参联等是有效成分,摘录,和中药配方,以改善IHD。这些活性化合物,Extract,中药通过延缓心室重构来治疗IHD,减少心肌纤维化,减少活性氧,调节心肌能量代谢,改善炎症,减轻细胞凋亡,和许多其他方面。
结论:网络药理学为理解中药治疗IHD提供了一个新的研究范例。然而,网络药理学在中医研究中的应用还停留在肤浅的水平上。通过合理地结合人工智能技术和网络药理学,分子生物学,代谢组学,和其他先进的理论和技术,系统地研究产品之间的代谢过程和网络,目标,从临床角度分析中药的应用途径可能是网络药理学的一个潜在发展趋势。
BACKGROUND: The field of network pharmacology showed significant development. The concept of network pharmacology has many similarities to the philosophy of traditional Chinese medicine (TCM), making it suitable to understand the action mechanisms of TCM in treating complex diseases, such as ischemic heart diseases (IHDs).
OBJECTIVE: This review summarizes the representative applications of network pharmacology in deciphering the mechanism underlying the treatment of IHDs with TCM.
METHODS: In this report, we used \"ischemic heart disease\" OR \"coronary heart disease\" OR \"coronary artery disease\" OR \"myocardial ischemia\" AND (\"network pharmacology\" OR \"systematic pharmacology\") as keywords to search for publications from PubMed, the Web of Science, and Google Scholar databases and then analyzed the representative research reports that summarized and validated the active components and targets network of TCM in improving IHDs to show the advantages and deficiencies of network pharmacology applied in TCM research.
RESULTS: The network pharmacology research indicated that HGF, PGF, MMP3, INSR, PI3K, MAPK1, SRC, VEGF, VEGFR-1, NO, eNOS, NO3, IL-6, TNF-α, and more are the main targets of TCM. Apigenin, 25S-macrostemonoside P, ginsenosides Re, Rb3, Rg3, SheXiang XinTongNing, colchicine, dried ginger-aconite decoction, Suxiao Xintong dropping pills, Ginseng-Danshen drug pair and Shenlian and more are the active ingredients, extracts, and formulations of TCM to ameliorate IHDs. These active compounds, extract, and formulations of TCM treat IHDs by delaying ventricular remodeling, reducing myocardial fibrosis, decreasing reactive oxygen species, regulating myocardial energy metabolism, ameliorating inflammation, mitigating apoptosis, and many other aspects.
CONCLUSIONS: The network pharmacology supplies a novel research exemplification for understanding the treatment of IHDs with TCM. However, the application of network pharmacology in TCM studies is still at a superficial level. By rational combining artificial intelligence technology and network pharmacology, molecular biology, metabolomics, and other advanced theories and technologies, and systematically studying the metabolic process and the network among products, targets, and pathways of TCM from the clinical perspective may be a potential development trend in network pharmacology.